# A Study of a New LY900014 Formulation in Healthy Participants

> **NCT02525744** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LY900014
- **DRUG:** Insulin Lispro (Humalog)

## Key facts

- **NCT ID:** NCT02525744
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02525744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02525744, "A Study of a New LY900014 Formulation in Healthy Participants". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02525744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*